Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 27;108(6):1640–1651. doi: 10.3324/haematol.2021.280424

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2023 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 2. — Changes in first-line treatment over time for patients ≥75 years in (A) Denmark and (B) Sweden. Cd: cyclophosphamide, dexamethasone; CRd: cyclophosphamide, lenalidomide, dexamethasone; CTd: cyclophosphamide, thalidomide, dexamethasone; Mono: monotherapy; MP: melphalan, prednisolone; MPR: melphalan, prednisolone, lenalidomide; MPT: melphalan, prednisolone, thalidomide; MPV: melphalan, prednisolone, bortezomib; Rd: lenalidomide, dexamethasone; Td: thalidomide, dexamethasone; Td-ixa: thalidomide, dexamethasone, ixazomib; VCd: bortezomib, cyclophosphamide, dexamethasone; Vd: bortezomib, dexamethasone; VRd: bortezomib, lenalidomide, dexamethasone; VTd: bortezomib, thalidomide, dexamethasone.